Cancer Immunology – Products

This whitepaper explores the available technologies, key challenges and the growing impact of single-cell cloning.

This application note highlights the features of active-release beads compared to the established passive-release beads for the isolation, activation, cell expansion and desired early memory cell phenotype.

Transgene announces the publication in the Journal for ImmunoTherapy of Cancer (JITC) of a peer-reviewed article which illustrates that TG6050 induces profound immune remodeling of the tumor microenvironment in animal models.

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.

This article explores how cell-to-cell communication can be targeted for novel treatment methods.

Transgene (Euronext Paris: TNG), announces the conversion into equity of 32,999,999.57 euros of debt, drawn down under the outstanding current account advance with its majority shareholder TSGH.

New service enables identification of bispecific antibody candidates accelerating drug development.

Touchlight, announced a license agreement with GSK. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA™ (doggybone DNA™) technology for the development and production of mRNA-based products.

Harnessing the cytotoxic potential of T cells through immunotherapy has revolutionized cancer treatment, but the effectiveness of T-cell therapeutics is still limited in solid tumors.

AMP published a set of evidence-based recommendations for the analytical validation and reporting of tumor mutational burden (TMB) testing as a potential predictive biomarker for immune checkpoint inhibitor (ICI) therapies.